The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Hepatic Expression of Class I and Class Ii Major Histocompatibility Complex Molecules in Primary Biliary Cirrhosis: Effect of Ursodeoxycholic Acid
Abstract
Aberrant hepatic expression of HLA molecules has been shown to be present in primary biliary cirrhosis and may play a determining role in the pathogenesis of the disease. We have studied the effect of the long–term administration of ursodeoxycholic acid on hepatic HLA expression. Nine untreated patients with primary biliary cirrhosis, eight patients treated for at least a year with ursodeoxycholic acid and eight control subjects without hepatobiliary disease were compared. HLA expression was studied on liver biopsy sections using a direct immunofluorescence technique with specific monoclonal antibodies directed against class I or class II HLA molecules. Aberrant biliary HLA class II expression was not modified by chronic administration of ursodeoxycholic acid. In contrast, aberrant hepatocyte HLA class I expression was markedly reduced. Reduction in HLA class I expression may lead to decreased cytotoxic T cell–dependent lobular necrosis, which is thought to contribute to the progression of primary biliary cirrhosis to advanced stages. These findings suggest that the beneficial effect of ursodeoxycholic acid treatment in primary biliary cirrhosis could result not only from a reduction in the intrahepatic accumulation of cytotoxic bile acids but also from a reduction in immunological injury.(HEPATOLOGY 1990; 11: 12-15.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY
Bottazzo, G., Hanafusa, T., Pujol-Borrell, R., & Feldmann, M. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90629-3 · Cited by 1,256
A Molecular Basis for MHC Class II—Associated Autoimmunity
Todd, J. A., Acha-Orbea, H., Bell, J. I., Chao, N., Fronek, Z., Jacob, C. O., McDermott, M., Sinha, A. A., Timmerman, L., Steinman, L., et al. (1988) · Science · doi:10.1126/science.3368786 · Cited by 705
IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?
Poupon, R., Poupon, R., Calmus, Y., Chrétien, Y., Ballet, F., & Darnis, F. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91610-2 · Cited by 536
Self-citationBallardini, G., Bianchi, F., Doniach, D., Mirakian, R., Pisi, E., & Bottazzo, G. (1984) · The Lancet · doi:10.1016/s0140-6736(84)91108-5 · Cited by 488
Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies
REBAÏ, N., & MALISSEN, B. (1983) · Tissue Antigens · doi:10.1111/j.1399-0039.1983.tb01176.x · Cited by 196
Yamada, G., Hyodo, I., Tobe, K., Mizuno, M., Nishihara, T., Kobayashi, T., & Nagashima, H. (1986) · Hepatology · doi:10.1002/hep.1840060309 · Cited by 115
Rebaï, N., MALISSEN, B., Pierres, M., Accolla, R. S., Corte, G., & Mawas, C. E. (1983) · European Journal of Immunology · doi:10.1002/eji.1830130205 · Cited by 113
(1952) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1952.tb94634.x · Cited by 113
Shaw, S., Ziegler, A., & DeMars, R. (1985) · Human Immunology · doi:10.1016/0198-8859(85)90336-2 · Cited by 106
Immunohistochemical analysis of HLA (A, B, C) antigens in liver disease using a monoclonal antibody.
Barbatis, C., Woods, J., Morton, J. A., Fleming, K. A., McMichael, A., & McGee, J. O. (1981) · Gut · doi:10.1136/gut.22.12.985 · Cited by 90
Cited by
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Self-citationPaumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Self-citationBile-acid-induced cell injury and protection
Perez, M. J., & Briz, O. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1677 · Cited by 717
Molecular Pathogenesis of Cholestasis
Trauner, M., Meier, P. J., & Boyer, J. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391707 · Cited by 706
Molecular Pathogenesis of Cholestasis
Trauner, M., & Jansen, P. L. M. (2004) · Springer eBooks · doi:10.1007/978-1-4419-9034-1 · Cited by 610
Primary Sclerosing Cholangitis
Lee, Y.-M., & Kaplan, M. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321406 · Cited by 526
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448
Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417
Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’
Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00092-7 · Cited by 411
Züchner, D., Sternsdorf, T., Szostecki, C., Heathcote, E. J., Cauch-Dudek, K., & Will, H. (1997) · Hepatology · doi:10.1002/hep.510260506 · Cited by 404
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242
Färkkilä, M., Karvonen, A., Nurmi, H., Nuutinen, H., Taavitsainen, M., Pikkarainen, P., & Kärkkäinen, P. (2004) · Hepatology · doi:10.1002/hep.20457 · Cited by 218
Bosch, A., Dumortier, J., Maucort-Boulch, D., Scoazec, J.-Y., Wendum, D., Conti, F., Morard, I., Rubbia-Brandt, L., Terris, B., Radenne, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.038 · Cited by 114
Self-citationColombato, L. A., Alvarez, F., Côté, J., & Huet, P.-M. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90829-x · Cited by 104
Nakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Angulo, P., Jorgensen, R. A., & Lindor, K. D. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05270.x · Cited by 39
Heathcote, J. E., Cauch-Dudek, K., Walker, V., Bailey, R. J., Blendis, L. M., Ghent, C. N., Michieletti, P., Minuk, G. Y., Pappas, C. S., Scully, L. J., et al. (1994) · Hepatology · doi:10.1002/hep.1840190512 · Cited by 2
Metadata
- Authors
- Calmus, Y., Gane, P., Rouger, P., & Poupon, R.
- Venue
- Hepatology
- Published
- 1990-01
- Volume
- 11
- Issue
- 1
- Pages
- 12-15
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2013605037
- Cited by
- 303
- References
- 14
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.